Abstract: The present invention relates to a composition for the diagnosis of a degenerative brain disease, comprising hpmA, which is a substance derived from Proteus, Shigella, Klebsiella pneumoniae, or Citrobacter, preferably a Proteus mirabilis strain, from a biological sample of a subject. In addition, the present invention relates to a method for providing information for the diagnosis of a degenerative brain disease such as Parkinson's disease, brain neuritis (neuroinflammation), or Alzheimer's disease, by measuring the amount of hpmA.

Abstract: An optical path control member according to an embodiment comprises: a first substrate; a first electrode provided on the upper portion of the first substrate; a second substrate provided on the first substrate; a second electrode provided on the lower portion of the second substrate; and an optical conversion unit provided between the first electrode and the second electrode, wherein the optical conversion unit comprises partition wall parts and accommodation parts which are alternately arranged. The accommodation parts have a light transmission rate that varies according to the application of a voltage, and the accommodation parts comprise a plurality of unit accommodation cells spaced apart from each other, and comprises a dispersion and light-absorbing particles which are dispersed in the dispersion.

Abstract: A quantum dot including a core that includes a first semiconductor nanocrystal including zinc and selenium, and optionally sulfur and/or tellurium, and a shell that includes a second semiconductor nanocrystal including zinc, and at least one of sulfur or selenium is disclosed. The quantum dot has an average particle diameter of greater than or equal to about 13 nm, an emission peak wavelength in a range of about 440 nm to about 470 nm, and a full width at half maximum (FWHM) of an emission wavelength of less than about 25 nm. A method for preparing the quantum dot, a quantum dot-polymer composite including the quantum dot, and an electronic device including the quantum dot is also disclosed.

Abstract: An optical path control member according to an embodiment comprises: a first substrate; a first electrode disposed on the first substrate; a second substrate disposed on the first substrate; a second electrode disposed under the second substrate; and a photoconversion unit disposed between the first electrode and the second electrode, wherein the second substrate includes at least one hole penetrating the second substrate, and an electrode connection part connected to a side surface of the second electrode is disposed inside the hole.

Abstract: The present invention relates to a composition for an organic optoelectronic device, and an organic optoelectronic device and display device comprising same, the composition including a first compound represented by Chemical Formula 1 and a second compound represented by Chemical Formula 2, or a first compound represented by Chemical Formula 1 and a third compound represented by a combination of Chemical Formula 3 and Chemical Formula 4. The details of Chemical Formula 1 to Chemical Formula 4 are as defined in the specification.

Abstract: A liquid crystal retardation film, a polarizing plate for light emitting displays including the same, and a light emitting display including the same are provided. The liquid crystal retardation film includes: a first retardation layer having no alignment layer, a UV absorbent primer layer, and a second retardation layer sequentially formed in the stated order, wherein each of the first retardation layer and the second retardation layer may be a liquid crystal layer.

Abstract: There is provided a binder, which binds to CD47 overexpressed in cancer cells and has an improved binding affinity for CD47, and a liposome complex. There is also provided a binder, which binds to CD47 overexpressed in cancer cells and includes an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2, and a binder-conjugated liposome complex, in which the binder is conjugated to a liposome.

Abstract: There is provided a polynucleotide for cancer treatment, which is a novel polynucleotide for cancer treatment, is used in the form being captured in liposomal nanoparticles that form a complex with a binder that binds to CD47 and has a mechanism to kill cancer cells by maximizing the metabolic vulnerability of cancer cells. There is also provided a polynucleotide for cancer treatment, encoding an amino acid sequence represented by SEQ ID NO: 3.

Abstract: There is provided a liposome complex for cancer treatment including a novel CD47 binder and a polynucleotide, in which the liposome complex has a mechanism to kill cancer cells by maximizing the metabolic vulnerability of cancer cells. There is also provided a complex for cancer treatment, which includes a polynucleotide encoding an amino acid sequence represented by SEQ ID NO: 3, a liposome in which the polynucleotide is captured, and a binder which is conjugated to the liposome, binds to CD47 overexpressed in cancer cells, and includes an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2.

Abstract: Disclosed are a compound for an organic optoelectronic device represented by Chemical Formula 1, a composition for an organic optoelectronic device including the same, an organic optoelectronic device, and a display device. Details of Chemical Formula 1 are as defined in the specification.

Abstract: A compound for an organic optoelectronic device, a composition for an organic optoelectronic device including the same, an organic optoelectronic device, and a display device, the compound being represented by Chemical Formula 1:

Abstract: A compound for an organic optoelectronic device, a composition for an organic optoelectronic device, an organic optoelectronic device, and a display device, the compound being represented by Chemical Formula 1:

Abstract: A compound for an organic optoelectronic device, a composition for an organic optoelectronic device including the same, an organic optoelectronic device, and a display device, the compound being represented by Chemical Formula 1:

Abstract: Provided is a composition for preventing or treating obesity including a mixed extract of Cinnamomi twigs, and more particularly, a pharmaceutical composition for preventing or treating obesity including a mixed extract of Cinnamomi twigs and Moutan root bark, a health functional food composition of feed composition for preventing or alleviating obesity including the composition, and a method of preventing or treating obesity including administering the pharmaceutical composition to an individual having obesity or a risk of developing obesity. The mixed extract of Cinnamomi twigs and Moutan root bark may inhibit fat absorption in the intestinal tract and increases in body weight causing obesity by single-dose administration, reduce lipid content in the blood, decrease weight and size of adipocytes, effectively inhibit accumulation of fat in liver tissue, and inhibit diarrhea, a serious side effect of Xenical™, by long-term administration.

Abstract: The present invention relates to a pharmaceutical composition for preventing, treating or alleviating cancer, containing a PLK1 inhibitor as an active ingredient, and a compound according to the present invention selectively binds to PBD of PLK1, thereby having advantages of high selectivity and binding affinity for PLK1 and low toxicity. Therefore, a PLK inhibitor compound according to the present invention can be effectively used as an anticancer agent by inhibiting the growth of various cancer cells, and can be expected to exhibit synergistic effects with existing developed anticancer agents through co-administration, in addition to individual administration thereof.

Abstract: A composition for an organic optoelectronic device, an organic optoelectronic device including the same, and a display device, the composition including a first compound represented by Chemical Formula 1, and a second compound represented by a combination of Chemical Formula 2 and Chemical Formula 3:

Abstract: Provided is a polarizing plate for a light-emitting diode and a light-emitting display device including the same, the polarizing plate comprising a polarizing film and a liquid crystal retardation film, wherein the liquid crystal retardation film comprises a laminate made of: a second retardation film having a discotic liquid crystal of which an in-plane retardation Re, in a wavelength of 550 nm, is approximately 220 nm to approximately 280 nm and a biaxial degree (NZ) is approximately 0 to approximately 0.3; and a first retardation film having a nematic liquid crystal of which an in-plane retardation Re, in a wavelength of 550 nm, is approximately 100 nm to approximately 150 nm and a biaxial degree (NZ) is approximately 0.3 to approximately 0.7.

Abstract: The extract of a mixture of cinnamon twig and moutan root bark, cinnamon twig and peony root, or cinnamon twig and poria according to the present invention has been confirmed to inhibit the excessive generation of advanced glycation end-products, which occurs under chronic diabetic conditions, exhibit the effect of fragmentizing a cross-link between the advanced glycation end-products and matrix proteins, have an excellent effect in inhibiting the generation of the advanced glycation end-products in a human retinal pigment epithelial cell line subjected to a hyperglycemic or aging environment, and have excellent effects in delaying, preventing, and treating diabetic complications, muscular degeneration, commotio retinae, and lower extremity edema in various animal models of diabetic complications, macular degeneration, and lower extremity edema, and thus the mixture extract can effectively be used as an active ingredient for a composition for preventing and treating diabetic complications, including diabetic

Abstract: Disclosed is a method for producing soluble CRM197 protein at high yield by overexpressing the protein in the cytoplasm of E. coli. The method includes a step of culturing recombinant E. coli harboring an expression plasmid carrying a gene sequence coding for a recombinant CRM197 protein under a condition suitable for expression of the recombinant CRM197 protein which has a histidine-tag attached to the C-terminus of CRM197 and a maltose-binding protein (MBP) attached to the N-terminus of CRM197. The method further includes a step of purifying after the culturing, wherein the step of purifying comprises a step of treating with tobacco etch virus (TEV) protease to remove the maltose-binding protein and a step of removing the histidine-tag via histidine-tag affinity chromatography.

Abstract: Provided is a composition for preventing or treating obesity including a mixed extract of Cinnamomi twigs, and more particularly, a pharmaceutical composition for preventing or treating obesity including a mixed extract of Cinnamomi twigs and Moutan root bark, a health functional food composition of feed composition for preventing or alleviating obesity including the composition, and a method of preventing or treating obesity including administering the pharmaceutical composition to an individual having obesity or a risk of developing obesity. The mixed extract of Cinnamomi twigs and Moutan root bark may inhibit fat absorption in the intestinal tract and increases in body weight causing obesity by single-dose administration, reduce lipid content in the blood, decrease weight and size of adipocytes, effectively inhibit accumulation of fat in liver tissue, and inhibit diarrhea, a serious side effect of Xenical™, by long-term administration.